pep-04832 v1 CC-BY-SA-4.0
Blood-pressure-lowering peptide (DAYPSGA)
A small peptide that blocks ACE, the enzyme that raises blood pressure; studied as a potential treatment for high blood pressure. Experimental, not yet an approved drug.
status
Someone proposed this peptide.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
A computer predicted how the peptide binds to its target.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
Someone else ran the same prediction and got the same result.
A second contributor repeated the computation on their own hardware and the scores matched.
SYNTHESIZED — literature evidence
Literature-extracted sequence peptide — synthesized for bioassay as documented in linked reference(s)
Fork this card to add platform evidence →
BIOASSAYED — literature evidence
Activity measured in linked reference(s) — IC50/MIC/cytotoxicity data
Fork this card to add platform evidence →
prediction metrics
ipTM0.850
pTM0.634
avg pLDDT89.5
ranking score0.886
STRUCTURE · PEP-04832 × ACE
ranking0.886
target interface 4.5Å peptide drag rotate · ctrl+scroll zoom · right-click pan
sequence
157
DAYPSGA
details
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.849571943283081 | boltz-2 |
| ranking score | 0.8857671618461609 | boltz-2 |
▸3-letter notation
Asp-Ala-Tyr-Pro-Ser-Gly-Ala
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | colabfold_nvidia |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-25 |
▸citationbibtex
peptidemodel (2026). Blood-pressure-lowering peptide (DAYPSGA) (pep-04832, v1). PeptideModel. https://peptidemodel.com/card/pep-04832
@peptide{pep04832,
sequence = {DAYPSGA},
target = {ace},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
} related peptides
references
discussion
sign in to comment